Overview of NovoMix 30

Defining NovoMix 30: An Insulin Analogue for Glycaemic Control

Property	Description
Active ingredient	Insulin aspart
Form	Suspension for subcutaneous injection
Pharmacological class	Antidiabetic agent / Blood glucose lowering agent
Common use	Management of diabetes mellitus (Type 1 and Type 2)
Origin	Synthetic analogue (via recombinant DNA technology)

NovoMix 30 is a prescription-only, biphasic insulin analogue classified as an antidiabetic agent used to manage diabetes mellitus. It is a blood glucose lowering agent that acts as a substitute for the body's natural insulin, helping to move glucose from the bloodstream into cells for energy. The active ingredient, insulin aspart, is a synthetic derivative of human insulin produced via advanced recombinant DNA technology. This molecular modification gives it a faster absorption rate and speed of action compared to human insulin, characterizing its accelerated profile.

What is the 30/70 Composition?

The medicine is a pre-mixed neutral suspension for subcutaneous injection, defined by its precise 30/70 ratio of the active substance, insulin aspart. This combination product consists of two components: 30% soluble insulin aspart, which is the rapid-acting component, and 70% protamine-crystallised insulin aspart, which provides the necessary intermediate-acting component. This combination is intended to cover both immediate mealtime needs and prolonged, sustained insulin needs. This specific dual-component structure is a defining feature, positioned to simplify the insulin regimen.

How This Dual-Action Structure Benefits Diabetes Management

The core benefit of this dual-action structure is its ability to provide comprehensive insulin coverage in a single preparation, helping achieve effective glycaemic control. The rapid-acting portion is absorbed quickly, managing the anticipated rise in blood glucose that occurs immediately after a meal. Conversely, the intermediate-acting portion ensures the slow, sustained release of insulin over an extended duration, stabilizing glucose levels between meals and throughout the night. This synchronized action profile is suited to help patients maintain more consistent blood sugar levels, offering a balanced approach to the essential treatment of diabetes mellitus.

Regulatory References

MedlinePlus: Insulin Aspart Drug Information

What side effects are possible with NovoMix 30?

Possible Side Effects and Safety Information for NovoMix 30

The official safety profile of NovoMix 30 is defined by adverse reactions categorized by frequency and the body systems they affect, as documented in government regulatory sources. The most critical and Very Common (1 in 10 patients) safety event is hypoglycaemia (low blood glucose levels), which is the primary risk inherent to all insulin therapy.

Official Adverse Reaction Classifications

Adverse reactions are grouped according to the physiological system involved. Skin and Subcutaneous Tissue Disorders are common, including Injection Site Reactions (e.g., pain, redness), classified as Common. Less frequent, Uncommon effects include Lipodystrophy (skin thickening or pitting) and transient Peripheral Oedema (swelling in the limbs), which, along with visual problems, are often observed at the beginning of treatment or during intensive glucose control. Cutaneous Amyloidosis (lumps under the skin) is also documented.

Serious Reactions and Safety Constraints

While rare, the regulatory profile includes Serious Adverse Reactions, such as Severe Hypoglycaemia (which may be life-threatening) and Anaphylaxis (a severe generalized allergic reaction). Hypokalaemia (low potassium levels) is also a documented risk. Safety statements also address specific populations and co-medications:

Population Notes: Dosage requirements may be reduced in patients with Renal or Hepatic Impairment, and intensified glucose monitoring is noted for Older Adults.
Co-medication Risk: Use with Thiazolidinediones (TZDs) is associated with the risk of fluid retention and potential congestive heart failure, as specified in regulatory labeling.

Overdose and Emergency Response

Overdose and When to Seek Help

The main consequence of administering an excess amount of insulin, relative to the body's needs, is hypoglycaemia (low blood glucose). Regulatory documents indicate that a specific overdose dose for insulin is not definable, but toxicity develops as blood sugar levels drop too low.

Documented Overdose Manifestations

Symptoms are typically categorized by severity:

Mild Hypoglycaemia: May include cold sweat, paleness, nervousness, tremor, rapid heartbeat, fatigue, confusion, headache, and nausea.
Severe Hypoglycaemia: Characterized by central nervous system impairment, potentially leading to disorientation, convulsions, or loss of consciousness. Severe hypoglycaemia may result in temporary or permanent impairment of brain function and is potentially fatal.

Immediate Emergency Actions

Urgent medical attention must be sought immediately if a patient loses consciousness due to low blood sugar.

Mild Episodes: Can typically be treated by the oral intake of sugar or sugary products.
Severe Episodes: Requires immediate administration of glucagon (subcutaneously or intramuscularly) by a trained person or intravenous glucose by a medical professional. Intravenous glucose must be given if the patient does not respond to glucagon within 10 to 15 minutes.

Patients who are unconscious should be turned onto their side and should not be given anything to eat or drink. The overdose structure primarily focuses on rapid identification and reversal of acute low blood sugar to mitigate the risk of serious neurological harm.

Therapeutic Uses of NovoMix 30

NovoMix 30 is used across the core therapeutic domain of Diabetes Mellitus. It is applied in situations where the body requires insulin therapy to help control symptoms related to the elevated blood sugar levels (hyperglycemia) associated with these conditions. The medicine plays a role in managing this systemic imbalance by providing necessary insulin replacement in adult, adolescent, and pediatric patients commonly affected by these conditions.

Controlling Dual Glucose Patterns: Targeting Fluctuations

This medication provides dual therapeutic action, addressing blood sugar surges associated with meal consumption and the continuous, lower requirement for insulin needed to stabilize glucose between meals and overnight. This dual control supports the management of pronounced symptomatic patterns that interfere with daily comfort.

Quick Fact: Targeting Glucose Fluctuations

This insulin is commonly used to help manage both the acute, post-meal spike in blood sugar after eating and the sustained, background levels that occur during fasting periods.

Supporting a Simplified Insulin Regimen

NovoMix 30 is generally considered relevant in clinical scenarios where patients may benefit from a simplified insulin regimen. By combining the components necessary for both immediate mealtime coverage and sustained background support into a single preparation, it helps patients cope more steadily with the logistics of daily insulin administration, contributing to easing the overall symptom load.

Regulatory References

European Medicines Agency (EMA) overview

Eligibility and Restrictions for Use

NovoMix 30 (biphasic insulin aspart) eligibility is strictly defined by regulatory documents based on pre-existing conditions, age, and physiological status.

Contraindications (Must Not Use)

Hypoglycemia: Contraindicated during episodes of low blood sugar.
Hypersensitivity: Contraindicated in patients with a known allergy to insulin aspart or any of the excipients.
Administration Method: Must not be administered intravenously or used in insulin infusion pumps.

Age-Related Eligibility

Age Group	Eligibility Status
Adults	Approved (Indicated population)
Adolescents (ge 10 yrs)	Approved (When premixed insulin is preferred)
Children (6–9 yrs)	Limited clinical data exist
Children (<6 yrs)	Use not established (No data available)
Older Adults (ge 65 yrs)	Can be used; limited experience in patients >75 years on combination therapy.

Condition-Specific Restrictions

Renal/Hepatic Impairment: Use is permitted, but the label mandates intensified glucose monitoring and individual dose adjustment, as these impairments may reduce the body's insulin requirements.
Pregnancy: There is limited clinical experience; intensified monitoring is recommended throughout pregnancy.
Lactation (Breastfeeding): No restrictions on treatment are noted in regulatory documents.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The official interaction profile for NovoMix 30 (Insulin Aspart) is structured around pharmacodynamic outcomes that affect blood glucose regulation, as documented in government regulatory sources. These interactions are classified by their resulting effect on the primary action of the insulin analogue.

Pharmacodynamic Effects on Glucose Control

Co-administration with other substances is categorized based on whether it increases or decreases the blood glucose-lowering action of NovoMix 30.

Interaction Type	Examples of Interacting Substances	Official Outcome Description
Reinforcement (Increased Glucose-Lowering Effect)	Oral antidiabetic products, ACE inhibitors, MAOIs, Salicylates, Anabolic steroids.	May potentiate the blood glucose-lowering effect, increasing the risk of hypoglycemia.
Attenuation (Reduced Glucose-Lowering Effect)	Glucocorticoids (corticosteroids), Oral contraceptives, Thiazide diuretics, Thyroid hormones, Growth hormone.	May reduce the blood glucose-lowering effect, leading to a tendency toward hyperglycemia.

Mechanism of Action

NovoMix 30 is a biphasic insulin formulation consisting of rapid-acting soluble insulin aspart and intermediate-acting protamine-crystallized insulin aspart. Both components function as agonists, binding to the insulin receptor (IR) on the cell surface, which initiates an intracellular phosphorylation cascade. This signaling pathway facilitates the translocation of Glucose Transporter type 4 (GLUT4) from the cytoplasm to the plasma membrane, primarily in muscle and adipose tissue. Increased GLUT4 presence enables the swift uptake of glucose into the cells, resulting in the reduction of extracellular glucose concentration. The protamine-bound component forms hexamers that slowly dissociate over time, prolonging the active life of the intermediate-acting insulin aspart to provide sustained receptor signaling.

Dosage and Administration Information

How to Use NovoMix 30: Official Administration Guidelines

NovoMix 30 is a pre-mixed, biphasic insulin analogue administered strictly via subcutaneous injection. Its usage protocol is highly individualized and determined by the patient's metabolic needs, requiring regular monitoring of blood glucose levels. The dosage is not fixed, but is continually adjusted based on blood glucose readings over the previous days.

Official Administration Pattern

Entity	Instruction Principle
Route of Administration	Subcutaneous injection only; intravenous and intramuscular administration is prohibited.
Timing in Relation to Meals	Must be injected immediately before a main meal or, if necessary, soon after the meal commences.
Preparation	The suspension must be gently re-suspended to a uniform, cloudy appearance immediately prior to each use.
Dosing Frequency	Typically administered once, twice, or three times daily, synchronized with main meals.
Injection Site Rotation	Injection sites must be rotated within approved body regions (e.g., abdomen, thigh) to minimize tissue reactions.
Pediatric Use	Approved for use in children and adolescents aged 10 years and above.
Device Constraint	The product is not approved for use in continuous subcutaneous insulin infusion pumps.

Usage in Clinical Practice

NovoMix 30 is characterized as a mealtime-synchronized injectable that requires a specific preparation step (resuspension) before delivery. For adults with Type 2 diabetes, common initiation options are 6 Units at breakfast and 6 Units at dinner, or a single injection of 12 Units at dinner. Doses may be reduced in patients with kidney or liver impairment, necessitating intensified glucose monitoring. The treatment is intended for long-term management of diabetes mellitus.

Recent Clinical Evidence

Research Evidence / Overview of Studies for NovoMix 30

The research foundation for NovoMix 30 includes clinical studies that research examined how this pre-mixed insulin analogue was studied for use in patients with different forms of diabetes. This overview details the types of research conducted, the outcomes measured, and the known limitations or gaps in the evidence, adhering strictly to official regulatory documents and scientific literature.

Evidence Base for Use in Type 2 Diabetes Mellitus ( T2DM)

The most extensive body of evidence for NovoMix 30 was evaluated in adults with Type 2 Diabetes Mellitus. This research primarily relies on Randomized Controlled Trials (RCTs) and Non-interventional Observational Studies that applied in studies examining patient-reported experiences.

These studies was studied for outcomes related to systemic or functional imbalance, with a focus on monitoring blood sugar levels. The primary marker researchers tracked was the long-term measure of blood sugar levels known as Glycosylated Haemoglobin ( HbA1c). Reports described patterns related to the glucose markers that were observed in some studies that used specific comparator treatments. The evidence is generally categorized as High based on the consistency and quantity of data evaluated in the clinical trials.

While the evidence gathered is substantial and are a component of the data considered for regulatory review, long-term effects are not fully established. A significant portion of the high-level evidence focuses on intermediate durations, typically spanning six months or less. This means that the research provides insight into short-term changes in HbA1c, but there is limited information for long-term outcomes related to complications like heart or vascular disease.

Evidence Base for Use in Type 1 Diabetes Mellitus ( T1DM)

Research for NovoMix 30 in people with Type 1 Diabetes Mellitus also primarily uses comparative Randomized Controlled Trials. These studies was evaluated in adults, adolescents, and children who require insulin replacement therapy. The main outcomes related to systemic or functional imbalance were monitored, including measurements of Glycosylated Haemoglobin ( HbA1c). Comparative studies describe patterns related to blood sugar markers that were observed across both groups, including those using other biphasic human insulin formulations. The evidence is generally categorized as Moderate, which contributes to the broader evidence landscape used by regulators for this population.

Research Gaps and Uncertainties

A key limitation in the overall research record is the heavy reliance on surrogate markers like HbA1c, meaning that the studies were primarily designed to track chemical changes in the blood rather than outcomes reflecting daily functioning or activity level or major long-term events. Additionally, data for certain groups remain insufficient. Clinical evidence is limited in children between 6 and 9 years of age, and no formal clinical data are available for children younger than 6 years of age. This means that research is ongoing and specific information about how symptoms evolved in these younger observed populations is uncertain.

Frequently Asked Questions (FAQ)

Common questions about NovoMix 30 (FAQ)

Q: How quickly does NovoMix 30 start to work after injection (onset of action)?

According to official product information, NovoMix 30 is a fast-acting insulin. Its blood sugar lowering effect typically begins within 10 to 20 minutes after being injected under the skin (subcutaneously).

Q: What is the peak effect time for NovoMix 30 after it is administered?

As a pre-mixed insulin, NovoMix 30 has a dual action. Official regulatory information indicates that the maximum blood sugar lowering effect for the total mixture occurs between 1 and 4 hours after the injection.

Q: How long can the total effect of NovoMix 30 last (duration of action)?

Official information indicates that the full duration of action for NovoMix 30 is relatively long, lasting up to 24 hours.

Q: What happens if a meal is delayed after taking NovoMix 30?

The medicine is designed to be synchronized with a meal due to its rapid action. Regulatory information states that patients typically need to have a meal or snack within 10 minutes of injection to help prevent blood sugar from dropping too low (hypoglycemia).

Q: What can be done to reduce the risk of low blood sugar while on NovoMix 30?

The risk of low blood sugar (hypoglycemia) is a primary safety concern with all insulin. Regulatory documents mention that factors like strenuous exercise or changes in diet can affect a person’s insulin needs. Patient information highlights the necessity for adequate awareness of this risk when performing activities such as driving.

Q: Why is it advised to be cautious about driving or operating machinery while on NovoMix 30?

Official warnings state that hypoglycemic reactions (episodes of low blood sugar) may occur. Because these reactions can impair a person's ability to concentrate and react, caution is officially advised when driving or operating machinery.

Q: Can NovoMix 30 be combined with oral anti-diabetic medications like metformin?

Yes, official labeling confirms that NovoMix 30 can be given in combination with oral antidiabetic drugs (pills used for diabetes) for which this combination with insulin is an approved treatment option.

Q: What general health conditions might require an adjustment to NovoMix 30 treatment?

Dose adjustments are noted as potentially necessary in regulatory information for people with renal or hepatic impairment (kidney or liver problems). Changes may also be needed during periods of illness and for pregnancy.

Q: Why do some people with long-standing Type 2 diabetes and heart conditions need extra monitoring when using NovoMix 30?

When NovoMix 30 is used in combination with certain other medications, specifically thiazolidinediones (TZDs), regulatory information notes it may be associated with an increased risk of fluid retention (oedema) and the potential for congestive heart failure.

Q: What is the main purpose of NovoMix 30 in diabetes management?

The main regulatory purpose of NovoMix 30 is the treatment of diabetes mellitus. It works by acting as a substitute for the body's natural insulin to effectively control blood sugar levels.

Q: How does the action profile of NovoMix 30 compare to a long-acting basal insulin?

NovoMix 30 is a biphasic (pre-mixed) insulin. This means it provides both a rapid-acting component to cover meals and an intermediate-acting component for sustained background coverage. This action profile differs from a long-acting basal insulin, which is designed to provide only the sustained, background component.

Q: Does NovoMix 30 commonly cause weight gain in people with diabetes?

Official safety documents list weight gain as an Uncommon side effect. This means it is reported to affect between 1 to 10 out of every 1,000 people using the medicine.

Q: What are the signs of a serious allergic reaction to NovoMix 30 that require immediate attention?

While rare, a serious allergic reaction (anaphylaxis) is possible. Official safety information lists key signs such as a widespread rash or hives, breathing difficulties (like shortness of breath or wheezing), and swelling of the face, lips, tongue, or throat.

Q: What should the mixture of NovoMix 30 look like immediately before injection?

Immediately before each use, the suspension must be gently mixed or resuspended. The regulatory patient information describes the final mixture as appearing uniformly white, cloudy, and aqueous (water-like).

Q: Why does NovoMix 30 need to be administered strictly via subcutaneous injection, and what happens if it's administered intravenously?

NovoMix 30 is formulated only for subcutaneous injection (under the skin). Regulatory information states that it must not be administered intravenously (into a vein), as this may result in a severe, sudden drop in blood sugar (severe hypoglycemia).

Q: How does exercising intensely affect blood sugar levels when taking NovoMix 30?

Official patient information indicates that unplanned, strenuous physical exercise can increase the risk of low blood sugar (hypoglycemia). This risk is similar to that associated with omitting a meal.

Q: What are the risks of using NovoMix 30 during pregnancy or while breastfeeding?

For pregnancy, official documents note that there is limited clinical experience, and intensified glucose monitoring is generally recommended. For lactation (breastfeeding), official documents state there are no restrictions on treatment.

Q: How can travel across time zones affect the schedule for taking NovoMix 30?

Traveling between different time zones can disrupt the required timing of meals and insulin injections. Regulatory documents state that patients should consult a healthcare professional before such travel, as this may necessitate a change in the timing of their insulin and meal schedule.

Q: Is it normal to see localized swelling (edema) or sudden weight gain when first using NovoMix 30?

Both localized swelling (peripheral oedema) and weight gain are listed as uncommon side effects. Official information notes that these effects are often observed in patients during the initial stages of their treatment.

Q: What is the longest amount of time NovoMix 30 can be kept at room temperature once in use?

Once a pen or cartridge is in use, it should be stored at a temperature of no more than 30 C (room temperature). The medicine can be kept under these conditions for a maximum of 4 weeks (28 days).

Q: Are there studies comparing NovoMix 30 to human premixed insulin 30/70?

Clinical studies have been conducted comparing NovoMix 30 to biphasic human insulin 30 (a human premixed insulin). These studies have found that NovoMix 30 demonstrated results that were closely comparable to the human premixed insulin formulation.

Q: Is NovoMix 30 available in different concentration options besides 100 U/mL?

NovoMix 30 is authorized and supplied at a standard concentration of 100 units/ml (100 U/mL).

Q: What is the difference between NovoMix 30 in a FlexPen versus a Penfill cartridge?

Both are delivery systems for the same medicine. A Penfill is a glass cartridge that is loaded into a separate, reusable insulin pen device. A FlexPen is a ready-to-use, pre-filled, disposable pen device that is discarded after the insulin is used up.

How should NovoMix 30 be stored and disposed of?

How to Store and Dispose of NovoMix 30

Storage Requirements

Unopened NovoMix 30 pens or cartridges must be stored in a refrigerator at a temperature between 2 C and 8 C. The medicine must be kept in its original outer carton to protect it from light and must be stored away from the cooling element of the refrigerator. Do not freeze the medicine, as freezing renders the insulin unusable.

Product State	Temperature Requirement	Maximum Duration
Unopened/Unused	2 C to 8 C (Refrigerated)	Until Expiration Date
In-Use/Spare	le 30 C (Room Temperature)	4 Weeks (28 days)

Handling and Disposal

Once in use, NovoMix 30 must not be returned to the refrigerator. The pen must be stored without the needle attached to prevent contamination and leakage. The medicine must always be kept out of the sight and reach of children. Used needles are considered sharps and must be disposed of safely in a designated puncture-proof sharps container. Unused or expired product should be disposed of according to local regulatory requirements.

NovoMix 30